Symphogenbased In Ballerupdenmarkis A Leader In Monoclonal Antibodymabtherapeuticsparticularly For Oncology And Immune Oncologyfounded In 2000 And Acquired By The Servier Group In 2020The Company Employs Around 150 Professionalswith A Strong Emphasis On Research And Developmentsymphogen S Team Is Dedicated To Advancing Innovative Antibody Therapiesfocusing On Antibody Discovery And Early Development The Company Specializes In Developing Mabs That Target Cancer Specific Mechanismsincluding Immune Evasion And Tumor Microenvironment Modulationsymphogen S Pipeline Features Over 30 Therapeutic Candidates Aimed At Various Cancerssuch As Metastatic Colorectal Cancer And Lung Cancercollaborations With Organizations Like Genentech And Shire Enhance Its Research Capabilities And Support Its Mission To Improve The Lives Of Cancer Patients Through Effective Treatmentssymphogen Is Committed To Scientific Excellence And Teamworkfostering A Motivated Workforce Dedicated To Advancing Healthcare Solutions
